Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen is a company focused on developing novel gene and cell therapies and vaccines to improve health for patients worldwide. Their pipeline includes potential treatments for various retinal diseases, such as inherited retinal diseases and age-related macular degeneration, as well as a potential COVID-19 vaccine. In March 2026, the company presented positive topline data from their Phase 2 ArMaDa study for their potential gene therapy for geographic atrophy (GA), with plans to initiate a Phase 3 study in 3Q26. With strong efficacy and safety data, as well as an expected launch in 2029, Ocugen's current stock price is expected to increase to $10.00 per diluted share.

Bears say

Ocugen is a high-risk investment due to its relatively small size and uncertainties surrounding its ability to successfully bring its products to market, making it a risky choice for investors. Additionally, the company's financials show a history of losses and negative cash flows, further highlighting the potential risks involved in investing in Ocugen.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.